Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837-842.

On page 841 in the 6 February 2014 issue, reference to a grant from the National Institutes of Health (NIH) was omitted. The Acknowledgment should have read, “Dr Zheng Zhou was supported by the National Institutes of Health (NIH) Hematology/Oncology Fellowship Training Grant (T32) provided to the Northwestern University Robert H. Lurie Comprehensive Cancer Center under the award number [PHS 5 T32 CA 79447-15]. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.”